<DOC>
	<DOC>NCT00603343</DOC>
	<brief_summary>The study was conducted between 2004 and 2006 to prove efficacy and tolerability of the antimuscarinic propiverine compared to placebo in children suffering from non-neurogenic overactive bladder and urinary incontinence.</brief_summary>
	<brief_title>Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence</brief_title>
	<detailed_description>This clinical trial showed superior efficacy of propiverine over placebo and convincing tolerability for the treatment of children suffering from OAB and urinary incontinence.</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Propiverine</mesh_term>
	<criteria>voiding frequency 8 or above per day at least one incontinence episode per day age between 510 years body weight between 17 and 45 kg normal age expected bladder capacity PVR more than 10 ml dysfunctional voiding neurogenic disorders UTI, constipation</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>antimuscarinics</keyword>
	<keyword>children</keyword>
	<keyword>overactive bladder</keyword>
	<keyword>propiverine</keyword>
	<keyword>urinary incontinence</keyword>
	<keyword>urotherapy</keyword>
</DOC>